{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:40:29Z","timestamp":1793580029080,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upregulation of DNA-dependent protein kinase (DNA-PK) is associated with poor prognosis and decreased response to DNA-damaging agents across cancer types. A Phase I\/IIa study (NCT03907969) investigated the highly potent, selective DNA-PK inhibitor AZD7648 as monotherapy or combined with pegylated liposomal doxorubicin (PLD) in patients with advanced cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty patients received escalating doses of AZD7648 as monotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914), starting at 5\u2009mg QD, or with PLD 40\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916). The primary objective was safety and tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AZD7648 monotherapy was administered at 5\u2013160\u2009mg BID. The most frequent class of adverse events was gastrointestinal disorders (9\/14 patients, 64.3%); one patient (160\u2009mg BID) experienced dose-limiting toxicities (DLTs). No responses to AZD7648 monotherapy were observed. The maximum dose of combination therapy was AZD7648 40\u2009mg QD days 1\u20137\u2009+\u2009PLD every 28 days. 13\/16 patients (81.3%) experienced gastrointestinal disorders and 11\/16 (68.8%) patients had anaemia. Three patients experienced DLTs (two at AZD7648 20\u2009mg QD 7 days + PLD; one at AZD7648 30\u2009mg QD 7 days + PLD). Limited efficacy was observed, with one RECIST partial response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Toxicity of AZD7648\u2009+\u2009PLD was greater than expected and antitumour activity was limited, leading to early study termination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03053-x","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:43:25Z","timestamp":1747471405000},"page":"168-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I\/IIa study"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-1326","authenticated-orcid":false,"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda G.","family":"Paulovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McMorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Oplustil O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marco-Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Gangl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-625X","authenticated-orcid":false,"given":"Mark J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-257X","authenticated-orcid":false,"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Zviezdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"3053_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.788","volume":"5","author":"G Federica","year":"2024","unstructured":"Federica G, Michela C, Giovanna D. Targeting the DNA damage response in cancer. MedComm (2020). 2024;5:e788.","journal-title":"MedComm"},{"key":"3053_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.14348\/molcells.2023.2164","volume":"46","author":"YR Lee","year":"2023","unstructured":"Lee YR, Kang GS, Oh T, Jo HJ, Park HJ, Ahn GO. DNA-dependent protein kinase catalytic subunit (DNA-PKcs): beyond the DNA double-strand break repair. Mol Cells. 2023;46:200\u20135.","journal-title":"Mol Cells"},{"key":"3053_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-23-1531","volume":"30","author":"A Laroche-Clary","year":"2024","unstructured":"Laroche-Clary A, Josensi C, Derieppe M-A, Belhomme S, Vendrely V, Perret R, et al. Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. Clin Cancer Res. 2024;30:629\u201337.","journal-title":"Clin Cancer Res"},{"key":"3053_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12836-9","volume":"10","author":"JHL Fok","year":"2019","unstructured":"Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019;10:5065.","journal-title":"Nat Commun"},{"key":"3053_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1158\/2159-8290.CD-14-0358","volume":"4","author":"JF Goodwin","year":"2014","unstructured":"Goodwin JF, Knudsen KE. Beyond DNA repair: DNA-PK function in cancer. Cancer Discov. 2014;4:1126\u201339.","journal-title":"Cancer Discov"},{"key":"3053_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1349-7006.2003.tb01372.x","volume":"94","author":"S Shintani","year":"2003","unstructured":"Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 2003;94:894\u2013900.","journal-title":"Cancer Sci"},{"key":"3053_CR7","first-page":"461","volume":"25","author":"Y Hosoi","year":"2004","unstructured":"Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461\u20138.","journal-title":"Int J Oncol"},{"key":"3053_CR8","first-page":"441","volume":"18","author":"N Tonotsuka","year":"2006","unstructured":"Tonotsuka N, Hosoi Y, Miyazaki S, Miyata G, Sugawara K, Mori T, et al. Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium. Int J Mol Med. 2006;18:441\u20137.","journal-title":"Int J Mol Med"},{"key":"3053_CR9","doi-asserted-by":"publisher","first-page":"e0145744","DOI":"10.1371\/journal.pone.0145744","volume":"10","author":"ME Dolman","year":"2015","unstructured":"Dolman ME, van der Ploeg I, Koster J, Bate-Eya LT, Versteeg R, Caron HN, et al. DNA-dependent protein kinase as molecular target for radiosensitization of neuroblastoma cells. PLoS ONE. 2015;10:e0145744.","journal-title":"PLoS ONE"},{"key":"3053_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.bjc.6605201","volume":"101","author":"C Beskow","year":"2009","unstructured":"Beskow C, Skikuniene J, Holgersson A, Nilsson B, Lewensohn R, Kanter L, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer. 2009;101:816\u201321.","journal-title":"Br J Cancer"},{"key":"3053_CR11","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3390\/cancers15164195","volume":"15","author":"A Karmokar","year":"2023","unstructured":"Karmokar A, Sargeant R, Hughes AM, Baakza H, Wilson Z, Talbot S, et al. Relevance of ATM status in driving sensitivity to DNA damage response inhibitors in patient-derived xenograft models. Cancers. 2023;15:4195.","journal-title":"Cancers"},{"key":"3053_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1535-7163.MCT-21-0420","volume":"21","author":"A Anastasia","year":"2022","unstructured":"Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, et al. The DNA-PK inhibitor AZD7648 sensitizes patient-derived ovarian cancer xenografts to pegylated liposomal doxorubicin and olaparib preventing abdominal metastases. Mol Cancer Ther. 2022;21:555\u201367.","journal-title":"Mol Cancer Ther"},{"key":"3053_CR13","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","volume":"27","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Karmokar A, Farrington PM, James NH, Ramos-Montoya A, Bickerton SJ, et al. Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control. Clin Cancer Res. 2021;27:4353\u201366.","journal-title":"Clin Cancer Res"},{"key":"3053_CR14","doi-asserted-by":"crossref","unstructured":"Goldberg FW, Finlay MRV, Ting AKT, Beattie D, Lamont GM, Fallan C, et al. The discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor. J Med Chem. 2020;63:3461\u201371.","DOI":"10.1021\/acs.jmedchem.9b01684"},{"key":"3053_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1021\/acsmedchemlett.2c00172","volume":"13","author":"FW Goldberg","year":"2022","unstructured":"Goldberg FW, Ting AKT, Beattie D, Lamont GM, Fallan C, Finlay MRV, et al. Optimization of hERG and pharmacokinetic properties for basic dihydro-8H-purin-8-one inhibitors of DNA-PK. ACS Med Chem Lett. 2022;13:1295\u2013301.","journal-title":"ACS Med Chem Lett"},{"key":"3053_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med. 2009;361:123\u201334.","journal-title":"New Engl J Med"},{"key":"3053_CR17","doi-asserted-by":"crossref","unstructured":"Aloss K, Hamar P. Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics. 2023;15:893.","DOI":"10.3390\/pharmaceutics15030893"},{"key":"3053_CR18","unstructured":"European Medicines Agency. ICH S9 Non-clinical evaluation for anticancer pharmaceuticals - scientific guideline. Available at: https:\/\/www.ema.europa.eu\/en\/ich-s9-non-clinical-evaluation-anticancer-pharmaceuticals-scientific-guideline."},{"key":"3053_CR19","doi-asserted-by":"crossref","unstructured":"Zhao L, Whiteaker JR, Pope ME, Kuhn E, Jackson A, Anderson NL, et al. Quantification of proteins using peptide immunoaffinity enrichment coupled with mass spectrometry. J Vis Exp. 2011;53:2812.","DOI":"10.3791\/2812"},{"key":"3053_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.765898","volume":"12","author":"JR Whiteaker","year":"2021","unstructured":"Whiteaker JR, Lundeen RA, Zhao L, Schoenherr RM, Burian A, Huang D, et al. Targeted mass spectrometry enables multiplexed quantification of immunomodulatory proteins in clinical biospecimens. Front Immunol. 2021;12:765898.","journal-title":"Front Immunol"},{"key":"3053_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1667\/RR14963.1","volume":"189","author":"JR Whiteaker","year":"2018","unstructured":"Whiteaker JR, Zhao L, Saul R, Kaczmarczyk JA, Schoenherr RM, Moore HD, et al. A multiplexed mass spectrometry-based assay for robust quantification of phosphosignaling in response to DNA damage. Radiat Res. 2018;189:505\u201318.","journal-title":"Radiat Res"},{"key":"3053_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41416-018-0286-4","volume":"119","author":"GN Jones","year":"2018","unstructured":"Jones GN, Rooney C, Griffin N, Roudier M, Young LA, Garcia-Trinidad A, et al. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. Br J Cancer. 2018;119:1233\u201343.","journal-title":"Br J Cancer"},{"key":"3053_CR23","doi-asserted-by":"crossref","unstructured":"Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, et al. Targeted mass spectrometry enables quantification of novel pharmacodynamic biomarkers of ATM kinase inhibition. Cancers. 2021;13:3843.","DOI":"10.3390\/cancers13153843"},{"key":"3053_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinetics. 2003;42:419\u201336.","journal-title":"Clin Pharmacokinetics"},{"key":"3053_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102217","volume":"9","author":"B Perez","year":"2024","unstructured":"Perez B, Aljumaily R, Marron TU, Shafique MR, Burris H, Iams WT, et al. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open. 2024;9:102217.","journal-title":"ESMO Open"},{"key":"3053_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","volume":"30","author":"PB Romesser","year":"2024","unstructured":"Romesser PB, Capdevila J, Garcia-Carbonero R, Philip T, Fernandez Martos C, Tuli R, et al. A phase Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer. Clin Cancer Res. 2024;30:695\u2013702.","journal-title":"Clin Cancer Res"},{"key":"3053_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","volume":"118","author":"M Samuels","year":"2024","unstructured":"Samuels M, Falkenius J, Bar-Ad V, Dunst J, van Triest B, Yachnin J, et al. A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int J Radiat Oncol Biol Phys. 2024;118:743\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3053_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41416-020-01151-6","volume":"124","author":"MTJ van Bussel","year":"2021","unstructured":"van Bussel MTJ, Awada A, de Jonge MJA, Mau-S\u00f8rensen M, Nielsen D, Sch\u00f6ffski P, et al. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. Br J Cancer. 2021;124:728\u201335.","journal-title":"Br J Cancer"},{"key":"3053_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ijc.28245","volume":"134","author":"JW Kim","year":"2014","unstructured":"Kim JW, Im SA, Kim MA, Cho HJ, Lee DW, Lee KH, et al. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker. Int J Cancer. 2014;134:72\u201380.","journal-title":"Int J Cancer"},{"key":"3053_CR30","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1158\/1538-7445.AM2013-4420","volume":"73","author":"MJ O\u2019Connor","year":"2013","unstructured":"O\u2019Connor MJ, Mason H, Horner S, Slater I, Lau A, Cadogan E, et al. Abstract 4420: generating preclinical models to assess bone marrow toxicity induced by the PARP inhibitor olaparib in combination with chemotherapy. Cancer Res. 2013;73:4420.","journal-title":"Cancer Res"},{"key":"3053_CR31","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-20-0502","volume":"20","author":"SJ Gill","year":"2021","unstructured":"Gill SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, Cairns J, Armenia J, et al. Radiopotentiation profiling of multiple inhibitors of the DNA damage response for early clinical development. Mol Cancer Ther. 2021;20:1614\u201326.","journal-title":"Mol Cancer Ther"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03053-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03053-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03053-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:42:57Z","timestamp":1781847777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03053-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8,10]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03053-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Timothy Yap has acted as a consultant for AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs and ZielBio. Ha has also has received grant\/research support from Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace and Zenith. Dr Yap is a stockholder in Seagen. Patricia LoRusso has acted as a consultant for AbbVie, I-Mab, Roivant Sciences, and Sotio and has served on advisory boards for ABL Bio, Acutate Therpeutics, Agenus, AstraZeneca, Atreca Development, BAKX Therapeutics, Boehringer Ingelheim, Compass BDAX, Cullinan, DAiNA, EMD Sereno, Glaxo-Smith Kline, I-Mab, imCheck, IQVIA, Kineta, Inc, Kyowa Kirin Pharmaceutical Development, Mekanistic, Mersana Therapeutics, Modifi Bio Molecular Template, NeuroTrials, Pfizer, Prelude, Qualigen, Quanta Therapeutics, Relay Therapeutics, Scenic Biotech, Schrodinger, Seagen, STCube Pharmaceuticals, Stemline, Takeda, Wells Therpeutics, Zai Lab, and Zentalis Pharmaceuticals. She has also served on Data Monitoring Committees for Sotio, Amgen CodeBreak 202 and a Data Safety Monitoring Board for DrenBio. Rowan Miller has acted as a consultant for Abbivie, AstraZeneca, Clovis Oncology, Ellipses, GI Innovation, GSK, MSD, Pharma&, and Shionogi, has been part of speaker bureaus for AstraZeneca, Clovis Oncology, GSK, and MSD, and has received trial funding from GSK and MSD. Rebecca Kristeleit has acted as a consultant for AstraZeneca, Celcuity, Clovis, Duke St Bio, Eisai, Epsilogen, GSK, ImCyte, Immunogen, Lucid, Merck AG, MSD, Pharma&, Prokarium, Seagen, Shattuck Labs, and Tubulis. She has also received travel expense from Epsilogen and Pharma& and been a member of Steering Committees for AstraZeneca, Eisai, GSK, and Merck AG. Amanda Paulovich is the Founder of Precision Assays, LLC. Stephen McMorn, Lenka Oplustil O\u2019Connor, Benedetta Lombardi, Paola Marco-Casanova, Eric Gangl, Emma Dean, and Roman Zviezdin are employed by and hold shares in AstraZeneca. Bharat Patel is a contractor for AstraZeneca. Ruth Plummer has received honoraria for attending advisory boards from AmLo, Astex Therapeutics, Bayer, BMS, Cybrexa Benevolent AI Ellipses, Genmab, Immunocore, Incyte, MSD, Nerviano, Novartis, Pierre Faber, and Sanofi Aventis and has been an Independent Data Monitoring Committee member for Alligator Biosciences, AstraZeneca, GSK, Onxeo, and SOTIO Biotech AG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}